• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Verweij, Jaap
    Van Oosterom, A
    Blay, Jean-Yves
    Judson, Ian R
    Rodenhuis, S
    Van der Graaf, W
    Radford, John A
    Le Cesne, Axel
    Hogendoorn, P C W
    Di Paola, E
    Brown, M
    Nielsen, O S
    Show allShow less
    Affiliation
    Department of Medical Oncology, Erasmus MC, University Medical Center Rotterdam, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands. verweij@onch.azr.nl
    Issue Date
    2003-09
    
    Metadata
    Show full item record
    Abstract
    The aim of this study was to assess the antitumour response and time to progression (TTP) of patients treated with imatinib mesylate (Glivec, Gleevec, formerly STI-571) who had advanced and/or metastatic gastrointestinal stroma tumours (GIST) or other soft tissue sarcomas (STS). Patients with measurable lesions and adequate organ function were entered. They were treated with imatinib mesylate at the dose of 400 mg twice daily (bid). All tumours were subject to a stringent pathological review by an expert panel. Immunohistochemical expression of KIT expression was evaluated. A total of 51 patients (27 GIST, 24 other STS), median age 53 years, median World Health Organization (WHO) performance score 1, were entered. 71% of the patients had received prior chemotherapy. The most frequent side-effects were anaemia (92%), periorbital oedema (84%), skin rash (69%), fatigue (76%), nausea (57%), granulocytopenia (47%) and diarrhoea (47%). Most of these side-effects were mild to moderate and no patient was taken off study due to side-effects. Skin rash and periorbital oedema frequently seem to be self limiting, despite continued treatment. In GIST patients, the current response rates (RRs) are 4% complete remission (CR), 67% partial remission (PR), 18% stable disease (SD) and 11% progression (PD). 73% of GIST patients are free from progression at 1 year. In the other STS group, there were no objective responses. The median time to progression in this subgroup was only 58 days. Imatinib mesylate is well tolerated at a dose of 400 mg bid. This dose is active in patients with KIT-positive GIST, but patients with other STS subtypes unselected for a molecular target are unlikely to benefit.
    Citation
    Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. 2003, 39 (14):2006-11 Eur. J. Cancer
    Journal
    European Journal of Cancer
    URI
    http://hdl.handle.net/10541/78982
    DOI
    10.1016/S0959-8049(02)00836-5
    PubMed ID
    12957454
    Type
    Article
    Language
    en
    ISSN
    0959-8049
    ae974a485f413a2113503eed53cd6c53
    10.1016/S0959-8049(02)00836-5
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
    • Authors: Wan DS, Wu XJ, Pan ZZ, Zhou ZW, Chen G, Li LR, Lu ZH, Ding PR
    • Issue date: 2006 Nov 21
    • A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.
    • Authors: Sawaki A, Yamao K, Nakamura T, Suzuki T, Okubo K, Hara K, Kawai H, Yamamura Y, Ito S, Mochiduki Y, Ohno R
    • Issue date: 2004
    • [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
    • Authors: Shen L, Jin ML
    • Issue date: 2004 Nov
    • Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    • Authors: Leahy M, Ray-Coquard I, Verweij J, Le Cesne A, Duffaud F, Hogendoorn PC, Fowst C, de Balincourt C, di Paola ED, van Glabbeke M, Judson I, Blay JY, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
    • Issue date: 2007 Jan
    • Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    • Authors: Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H
    • Issue date: 2002 Aug 15
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.